_pennystock版 - ARIA Up 39% After A Drug Study Showed Positive Results |
|---|
|
| 相关主题 |
|---|
| ● 期待ARIA今天能突破 | ● 推荐一个。LNET | | ● sppi | ● RDN挑这个日子上呀? | | ● 没人看见吗...ARNA终于还是悲剧了，看周一反应吧 | ● KOG, PPO, UXG, ACI, NSU | | ● AGM等了半天才买上 | ● csr | | ● CEDC | ● Tobacco: CIGX, UVV, PM, AOI, RAI | | ● CVO, INWK, DLX, DMC, RRD | ● stec | | ● 今天金融的破位大跌 | ● fslr | | ● CML | ● 高盛：稀土供应今年或出现史上最大缺口 zz |
|
|
|
|
f**********g
发帖数: 2252 | 1 Just saw the news, +39% now.
Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
Results (ARIA)
3 hours 7 minutes ago - PSM
Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
.33% higher at $6.79 after the company said that a study showed its drug for
sarcomas helped slow the disease's advance, according to a Bloomberg report
.
Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
price of $6.54 and an average consensus analyst price target of $6.67.
Ariad Pharmaceuticals is currently above its 50-day moving average (MA) of $
4.48 and above its 200-day of $3.76.
In the last five trading sessions, the 50-day MA has climbed 3.64% while the
200-day MA has risen 1.23%.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines
that regulate cell signaling with small molecules. The Company is primarily
focused on product candidates for targeted indications. ARIAD is developing
products to treat solid tumors, to block the spread of cancer, to treat
certain forms of leukemia, and to treat cancer that has spread to bone and
primary bone cancers. | v**********m
发帖数: 5516 | | B*****e
发帖数: 2413 | 3 I guess it will get another 39% in several weeks since sarcoma has over 10
billion market. Additionally that drug ri... also looks good for breast
cancer.
trading 29
for
report
【在 f**********g 的大作中提到】
: Just saw the news, +39% now.
: Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
: Results (ARIA)
: 3 hours 7 minutes ago - PSM
: Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
: .33% higher at $6.79 after the company said that a study showed its drug for
: sarcomas helped slow the disease's advance, according to a Bloomberg report
: .
: Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
: price of $6.54 and an average consensus analyst price target of $6.67.
| f**********g
发帖数: 2252 | 4 Just saw the news, +39% now.
Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
Results (ARIA)
3 hours 7 minutes ago - PSM
Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
.33% higher at $6.79 after the company said that a study showed its drug for
sarcomas helped slow the disease's advance, according to a Bloomberg report
.
Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
price of $6.54 and an average consensus analyst price target of $6.67.
Ariad Pharmaceuticals is currently above its 50-day moving average (MA) of $
4.48 and above its 200-day of $3.76.
In the last five trading sessions, the 50-day MA has climbed 3.64% while the
200-day MA has risen 1.23%.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines
that regulate cell signaling with small molecules. The Company is primarily
focused on product candidates for targeted indications. ARIAD is developing
products to treat solid tumors, to block the spread of cancer, to treat
certain forms of leukemia, and to treat cancer that has spread to bone and
primary bone cancers. | v**********m
发帖数: 5516 | | B*****e
发帖数: 2413 | 6 I guess it will get another 39% in several weeks since sarcoma has over 10
billion market. Additionally that drug ri... also looks good for breast
cancer.
trading 29
for
report
【在 f**********g 的大作中提到】
: Just saw the news, +39% now.
: Ariad Pharmaceuticals Shares Up 29% After A Drug Study Showed Positive
: Results (ARIA)
: 3 hours 7 minutes ago - PSM
: Comtex SmarTrend(R)Ariad Pharmaceuticals (NASDAQ:ARIA) shares are trading 29
: .33% higher at $6.79 after the company said that a study showed its drug for
: sarcomas helped slow the disease's advance, according to a Bloomberg report
: .
: Ariad Pharmaceuticals has a potential upside of 1.9% based on a current
: price of $6.54 and an average consensus analyst price target of $6.67.
|
|
|
|
|
|
|
